Follow-up of vascular-targeted photodynamic therapy in a real-world setting

Research output: Contribution to journalResearch articleContributedpeer-review



PURPOSE: Vascular-targeted photodynamic therapy (VTP) is an approved treatment option for unilateral low-risk prostate cancer (PCa).

METHODS: Patients with unilateral low- or intermediate-risk PCa undergoing hemiablation by VTP were evaluated in a real-world setting. Oncological outcome after VTP was measured by MRI-based re-biopsy at 12 and 24 months. Functional outcome after 1 year was investigated by IIEF-5 and IPSS questionnaires. Progression was defined as the evidence3 of ISUP ≥ 2 PCa.

RESULTS: At any control biopsy (n = 46) after VTP, only 37% of patients showed no evidence of PCa. Recurrence-free survival was 20 months (95% CI 4.9-45.5) and progression-free survival was 38.5 months (95% CI 33.5-43.6 months). In-field and out-field recurrent PCa occurs in 37% (55% ISUP ≥ 2 PCa) and 35% (56% ISUP ≥ 2 PCa). Seventy-nine percent of patients preserved erectile function, respectively. Ten percent of patients presented long-term bladder outlet obstruction. None of the patients presented incontinence.

CONCLUSION: Due to the high-recurrence in- and out-field recurrence rate in a mainly low-risk prostate cancer cohort, VTP has to be regarded critically as a therapy option in these patients. Pre-interventional diagnostic evaluation is the main issue before focal therapy to reduce the risk of tumor recurrence and progression.


Original languageEnglish
Article number55
Number of pages6
JournalWorld journal of urology
Volume42 (2024)
Issue number1
Publication statusPublished - 20 Jan 2024

External IDs

PubMedCentral PMC10799770
Scopus 85182659189


Sustainable Development Goals


  • Male, Humans, Follow-Up Studies, Treatment Outcome, Neoplasm Recurrence, Local/pathology, Prostatic Neoplasms/pathology, Photochemotherapy

Library keywords